Tikun Olam-Cannbit Pharmaceuticals Ltd.

As of December 31, 2025, Tikun Olam-Cannbit Pharmaceuticals Ltd. carries a market capitalization of 2.01B, placing it among publicly traded companies globally. Its enterprise value stands at 2.41B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Tikun Olam-Cannbit Pharmaceuticals Ltd. has 849,645.00 shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Tikun Olam-Cannbit Pharmaceuticals Ltd. maintains a current ratio of 0.06, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on August 18, 2026, Tikun Olam-Cannbit Pharmaceuticals Ltd.'s stock has declined approximately 96.49% over the past 52 weeks. The 50-day moving average sits at 665.62, while the 200-day moving average is 2,158.22.

As of December 31, 2025, Tikun Olam-Cannbit Pharmaceuticals Ltd. holds 3.00M in cash and equivalents against 1.18B in total debt, resulting in a net debt position of 1.14B. Total book value stands at -1.32B, with working capital of -1.95B providing operational flexibility.

Tikun Olam-Cannbit Pharmaceuticals Ltd.'s most recent stock split took place on March 2, 2026 with a 100:1 split ratio.